Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS117548 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | PLACEBO_COMPARATOR | One drop in each eye every 12 hours for seven days |
| Arm 2 | EXPERIMENTAL | One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days |
| Arm 3 | EXPERIMENTAL | One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days |
| Arm 4 | EXPERIMENTAL | One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | One drop in each eye every 12 hours for seven days |
| INS117548 | DRUG | One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days |
Inclusion Criteria: * Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma * Have best corrected visual acuity in both eyes of at least +0.5 or better Exclusion Criteria: * Are diagnosed with closed angle glaucoma, exfoliation syndrome or exfoliation glaucoma, an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
INS117548 is an investigational small molecule being developed for the treatment of glaucoma. It is formulated as an ophthalmic solution and is intended for use in patients with this condition. The drug is currently in clinical development, having completed a Phase 1 trial.
INS117548 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company conducted a Phase 1 clinical trial of the drug for the treatment of glaucoma.
INS117548 is in Phase 1 of clinical development. A Phase 1 trial of the drug has been completed. The drug is investigational and has not been approved by regulatory authorities. It is being studied for the treatment of glaucoma.
INS117548 has one completed clinical trial, registered as NCT00767793. This was a Phase 1, placebo-controlled, double-blind, randomized study of INS117548 ophthalmic solution in subjects with glaucoma. The trial enrolled 84 participants aged 18 years and older.
INS117548 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for glaucoma. The drug remains in clinical development and has not yet received regulatory approval for any use.